Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.

Saved in:
Bibliographic Details
Title: Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
Authors: Leon-Ferre RA; Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA. leonferre.roberto@mayo.edu.; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. leonferre.roberto@mayo.edu., Dimitroff K; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Yau C; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Giridhar KV; Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA., Mukhtar R; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Hirst G; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Hylton N; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Perlmutter J; Gemini Group, Ann Arbor, Michigan, USA., DeMichele A; University of Pennsylvania, Philadelphia, PA, USA., Yee D; University of Minnesota, Minneapolis, MN, USA., van 't Veer L; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Rugo H; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Symmans WF; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Goetz MP; Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA., Esserman L; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Boughey JC; Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.
Source: Breast cancer research : BCR [Breast Cancer Res] 2025 Jun 23; Vol. 27 (1), pp. 115. Date of Electronic Publication: 2025 Jun 23.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1465-542X
DOI:10.1186/s13058-025-02070-1